Maturation cervicale par misoprostol sur fœtus viable

Review of the current literature favors the use of vaginal misoprostol 25 μg three- to six-hourly equally to dinoprostone accordingly with previous French and international guidelines (World Health Organization and American College of Obstetricians and Gynecologist). The use of misoprostol 25 μg supposes a preparation by the pharmacist to ensure the safety of this precise posology. Medico-economic studies are warranted to attest an economic benefice to the use of misoprostol 25 μg in comparison to dinoprostone.